Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
60,220.84 -1,811.18 (-2.92%) CMC Crypto 200
1,262.02 -72.90 (-5.46%)
XBIT Oct 2024 15.000 call
| Previous close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.0000 |
| Ask | 2.3000 |
| Strike | 15.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 56 |
GlobeNewswireXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen
Simply Wall St.XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by...
GlobeNewswireXBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou
